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1. Introduction 
Prostaglandins (PGs), thromboxanes (TXs) and leukotrienes (LTs) collectively called 
eicosanoids, are cyclooxygenase (COX) and lipoxygenase (LOX) products. Prostanoids, PGs 
and TXs, are known effectors of a wide range of actions in most cells and tissues. They have 
been described to be involved in muscle contraction and relaxation, neurotransmitter 
release/unrelease, fever, sleep induction, apoptosis, cell proliferation and oncogenesis; but 
respecting endometriosis, what matters us mostly, is that they are central molecules 
involved in the reproductive system (Jabbour & Sales, 2004; Narumiya et al., 1999). 
1.1 Prostaglandin synthesis and function 
Arachidonic acid (AA) is the precursor of all eicosanoids. Phospholipase A2 splits AA from 
plasma membrane phospholipids; once free in the cytosol it is cyclized, oxygenated and 
reduced to the intermediary PGH2 by the COX enzymes; or to hydroperoxyeicosatetraenoic 
acid (HPETE) by LOX enzymes, when the LT pathway is followed. 
Two COX genes are known to be highly conserved throughout the species. COX-1 gene has 
several splice variants: the most widely known COX-1 enzyme, the less known counterparts 
COX-3 and other smaller variants of the COX-1 (Chandrasekharan et al., 2002; 
Chandrasekharan & Simmons, 2004). COX-2 gene has, up to now, only one known protein. 
COX-1 is ubiquitously and constitutively expressed. It was long thought of COX-1 as the 
enzyme that was involved only in physiological conditions, but was proven to be 
upregulated in various carcinomas and to be involved in tumorigenesis (Hwang et al., 1998; 
Kitamura et al., 2002; Sales et al., 2002). COX-2 enzyme is physiologically induced by growth 
factors and cytokines; it functions when the concentrations of AA are very low (Fortier et al., 
2008). Furthermore COX-2 was seen to be overexpressed in several pathological 
circumstances as different types of cancers, where its high expression correlates with a 
negative prognosis, and other inflammation related diseases, as endometriosis (Matsuzaki et 
al., 2004; Ota et al., 2001). 
PGH2 synthesized by the COXs, is used as a substrate to produce the terminal prostanoids 
by the PG synthases; each of them is named by their product: PGD2, PGE2, PGF2ǂ, 
prostacyclin (PGI2) and thromboxane (TX) A2 are produced by PGD synthase (PGDS), PGE 
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synthase (PGES), PGF synthase (PGFS), PGI synthase (PGIS) and TX synthase (TXS), 
respectively. Once synthesized prostanoids are rapidly exported by a PG transporter out of 
the cell and they function very close to their liberation site, in an autocrine or paracrine 
fashion. They exert their biological actions through G protein coupled receptors (GPCRs) 
and, as it happens with the synthases, each prostanoid has a distinctive receptor to which to 
bind to. DP, EP, FP, IP and TP are the receptors for PGD2, PGE2, PGF2ǂ, PGI2 and TXA2, 
respectively (Figure 1). The EP receptor has four known subtypes (EP1-EP4), each encoded 
by a different gene; furthermore, EP3 has eight splice variants; TP and FP have also been 
described to have two splice variants each (Fortier et al., 2008). 
Sequence homology analysis revealed that receptors sharing a common signaling pathway 
are more closely related than do receptors binding the same ligand. After binding to the 
corresponding GPCR there is generation of soluble second messengers. Coupled to Gq, DP 
receptor increases cyclic adenosine monophosphate (cAMP) concentration, whereas IP 
receptor is coupled to Gs and increases not only cAMP but also mediates responses by 
phosphatidylinositol increasing free Ca2+ concentration (Narumiya et al., 1999). Both 
isoforms of TP activate phopspholipase C (PLC), but TPǂ activates adenylate cyclase while 
TPǃ inhibits it (Narumiya et al., 1999). FP receptors also act through Gq, PLC and Ca2+ 
release; while EP receptors have distinctive signaling pathways depending on the subtype 
binding PGE2: EP1 is coupled to Gi and Ca2+ channels, EP2 and EP4 share the pathway 
coupling to Gs and increasing cAMP intracellular concentration, whereas the EP3 has 
specific responses depending on the splice variant, but is usually assumed as an inhibitory 
receptor coupled to Gi (Fortier et al., 2008) (Figure 1). 
2. Role of endometrial prostaglandins in reproduction 
The uterus plays a crucial role in the implantation process of the fertilized egg. Humans 
and old-world primates have the particularity that they shed part of their endometrium if 
fertilization or implantation does not take place. Consequently, endometrium is a 
dynamic tissue that undergoes regulated phases of proliferation, differentiation and 
degradation, cyclically. PGs are known to be important actors of this process; different 
reports have implicated COX enzymes and PGs in several stages of reproduction (Jabbour 
et al., 2006). 
COX-2 is physiologically expressed at different levels along the menstrual cycle. It has been 
shown to be expressed at its lowest level during ovulation and slightly start augmenting 
during the secretory phase, peaking at the late secretory and menstrual phases after which it 
starts decreasing again (Jones et al., 1997). 
The importance of COX and PGs in reproduction has been revealed from studies of 
knockout mice. Even if COX-1 deficient mice were fertile, their gestation period was 
prolonged while parturition and viable offspring were reduced. These findings 
demonstrated that COX-1 is essential for normal labor in the mouse (Gross et al., 1998; 
Jabbour et al., 2006). On the other side, selective COX-2 ablation impairs ovulation, 
fertilization and implantation; and a combined approach showed that COX-2 inhibition in 
COX-1(-/-) mice induced complete reproductive failure, suggesting a lack of alternative 
sources of PG synthesis (Reese et al., 2001). 
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Arachidonic acid is the precursor for leukotrienes and prostaglandins. Each prostaglandin has a specific 
seven transmembrane G protein coupled receptor; after binding with its receptor, prostaglandins 
produce the up (↓) or downregulation (↑) of second messengers. 
AA: arachidonic acid; LTs: leukotrienes; LOX: lipooxygenase; COX-1/2: cyclooxygenase-1 or 2; PGH2: 
prostaglandin H2; PGIS: prostacyclin synthase; PGI2: prostacyclin; TXS: thromboxane synthase; TXA2: 
thromboxane; PGE2: prostaglandin E2; PGD2: prostaglandin D2; PGF2: prostaglandin F2; PGES: PGE2 
synthase; PGDS: PGD2 synthase; PGFS: PGF2ǂ synthase; IP, TP┙/┚, EP1-4, DP, FP┙/┚: specific PG 
receptors; cAMP: cyclic adenosine monophosphate; IP3: inositol triphosphate; Ca2+: calcium.  
Fig. 1. Prostaglandin synthesis and signal transduction 
In addition, studies using EP and FP knockout mice have demonstrated the specific roles of 
PGE2 and PGF2ǂ in reproduction. It has been shown that EP2 receptors are essential for 
ovulation and fertilization (Kennedy et al., 1999; Ushikubi et al., 2000) and FP are 
indispensible for parturition (Sugimoto et al., 1998). These studies indicate not only the 
essential role of PGE2 in the fertilization process, but also the importance of PGF2ǂ in natural 
parturition.  
As well, it has been described that PGs serve as endogenous ligands for nuclear receptors. In 
this respect, other prostanoids were identified as good peroxisome proliferator-activated 
receptors (PPAR) agonists with varying specificity. 15-deoxy-Δ 12,14 prostaglandin J2 
(15dPGJ2), a natural PPARǄ ligand, has high affinity for PPARǄ and has been proposed as a 
regulator of the inflammatory response (Nosjean & Boutin, 2002; Scher & Pillinger, 2009). 
Another PPAR ligand is PGI2 that was found to play an important role via PPAR-ǅ nuclear 
receptor in implantation and decidualization (Pakrasi & Jain, 2008). 
The process of implantation is considered to be analogous to pro-inflammatory responses, 
hence the speculation that PGs play a role in this event (Kennedy, 1979; Maybin et al., 2011; 
Tranguch et al., 2005). As well, several nonsteroidal anti-inflammatory drugs (NSAIDs) and 
www.intechopen.com
 
Endometriosis - Basic Concepts and Current Research Trends 
 
118 
selective COX-2 inhibitors were implicated in the inhibition of endometrial vascular 
permeability and implantation in a variety of species (Diao et al., 2007; Sookvanichsilp & 
Pulbutr, 2002).  
In particular in the endometrium, COXs and PGs are known to be involved in the initiation of 
implantation and decidualization (Kennedy et al., 2007; Tranguch et al., 2005). It is well known 
that endometrial vascular permeability and proliferation and differentiation of endometrial 
stromal cells to decidual cells are mediated by PGs (Kennedy, 1979; Kennedy & Doktorcik, 
1988). The initial studies of Chakraborty and coworkers suggest an important role for PGs in 
the implantation process; specifically this report demonstrated that COX-2 expression during 
the blastocyst attachment is critical to implantation (Chakraborty et al., 1996). 
In an effort to identify which PGs are involved in the implantation process, different 
researchers have confirmed the presence of PGE and PGF receptors in the peri-implantation 
endometrium (Kennedy et al., 2007). However, no single type of PG has been unequivocally 
associated to this event. There may be species differences and also different PGs may be 
involved in the implantation or decidualization processes (Kennedy et al., 2007).  
3. PGE2 and its role in the aetiopathogenesis of endometriosis 
COX-2, the crucial enzyme for the production of PGs, has been described to be upregulated in 
different pathological inflammatory conditions. Endometriosis is characterized by the high 
proliferation rate of endometrial cells in an ectopic site, inflammation and pain. COX-2 is 
highly expressed in eutopic endometrium, both in the proliferative and secretory phases, and 
in ectopic lesions from endometriosis patients compared to disease free women (Ota et al., 
2001). Wu and coworkers also described that COX-2 is expressed in stromal and epithelial cells 
derived from endometriosis patients, and is in agreement with the work from Ota and 
coworkers, in that this expression is higher in patients (Ota et al., 2001; Wu et al., 2002).  
3.1 Sources of prostaglandins 
It is well known that the elevated levels of PGs found in the peritoneal fluid from patients 
with endometriosis are mainly produced by peritoneal macrophages and endometriotic 
tissues (Raiter-Tenenbaum et al., 1998; Wu et al., 2002; Wu et al., 2010). COX-2 is 
overexpressed in peritoneal macrophages and in ectopic and eutopic endometrial tissue 
derived from patients with endometriosis (Banu et al., 2008; Ota et al., 2001; Wu et al., 2002; 
Wu et al., 2005b). Peritoneal macrophages from endometriosis-free women express no or 
minimal amounts of COX-2, while the overexpression of COX-2 found in endometriosis has 
been associated with the elevated concentrations of PGs and the severity of the disease (Wu 
et al., 2002). Explicitly, induction of COX-2 expression correlated with the evidence that 
peritoneal macrophages from patients with endometriosis release significantly more PGE2 
and PGF2ǂ compared with peritoneal macrophages from control women (Karck et al., 1996; 
Raiter-Tenenbaum et al., 1998). Many pro-inflammatory and pro-angiogenic factors 
contribute to increase PGs levels: interleukin (IL)-1ǃ, tumor necrosis factor (TNF)-ǂ, vascular 
endothelial growth factor (VEGF), macrophage migration inhibition factor (MIF) and even 
PGE2 have been shown to induce COX-2 expression in peritoneal macrophages from women 
with endometriosis (Wu et al., 2002) and in endometrial and endometriotic stromal cells 
(Carli et al., 2009; Tamura et al., 2002; Wu et al., 2005b) (Figure 2).  
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The mitogenic effects of estrogens are mediated by the upregulation of several growth 
factors and also by PGs. Specifically, aromatase and steroidogenic acute regulatory protein 
(StAR) are known to be regulated by PGE2 in endometriotic stromal cells (Bulun et al., 2004; 
Noble et al., 1997; Sun et al., 2003; Tsai et al., 2001). PGE2 alone via the EP2/EP4 receptor is 
sufficient to induce de novo synthesis of estrogen from cholesterol (Attar et al., 2009). As 
well, estrogen further stimulates the synthesis of PGE2 in ectopic endometrial tissue (Bulun 
et al., 2000; Noble et al., 1997). In conclusion, estrogens, pro-inflammatory and pro-
angiogenic peptides contribute to elevate the expression of COX-2 and consequently the 
levels of PGE2 in endometriotic tissue and in peritoneal macrophages from patients with 
endometriosis (Figure 2). 
3.2 Regulation of aromatase activation and estrogen production by PGE2 
Aromatase is the key enzyme in the conversion of the androgens, androstenedione and 
testosterone, to estrone and estradiol (E2) respectively (Bulun et al., 2001). This protein was 
seen to be overexpressed in the eutopic endometrium of patients with endometriosis 
compared to controls (Noble et al., 1996) and it has been described to be expressed in the 
ectopic endometriotic lesion. PGE2 induces not only aromatase expression but also its 
activity, as seen in studies conducted in endometriotic stromal cells in vitro (Noble et al., 
1997); and its product, E2, induces COX-2 expression with the consequent synthesis of PGE2 
(Tamura et al., 2004). It is clear that given the way these molecules interact, a positive 
feedback loop is established favoring the activity of aromatase, provoking high levels of E2 
locally in the vicinity of the lesion (Figure 2). These high levels of E2 also give the 
endometriotic cells a high capability of proliferating; as it has been demonstrated that, 
through its estrogen receptor (ER)ǃ, E2 enhances stromal cell proliferation (Trukhacheva et 
al., 2009). 
Another mitogenic factor is fibroblast growth factor (FGF)-9. This molecule was found to be 
regulated by estrogen in endometriotic stromal cells in culture and, if added exogenously, 
cell proliferation was enhanced in a dose dependent manner. On the contrast, when cells 
were incubated with an aromatase or an ER inhibitor, the rate of cell proliferation 
diminished significantly compared to the untreated control (Wing et al., 2003). In the same 
study by Wing and coworkers, it was observed that not only FGF-9 is regulated by E2, but 
also, FGF receptors 2IIIc and 3IIIc. More recently, a study revealed that PGE2, acting through 
its receptor EP3 induces the expression of FGF-9 in a dose dependent manner in 
endometriotic cells in vitro (Chuang et al., 2006) (Figure 2). 
3.3 PGE2 and angiogenesis 
Endometrial cells at the ectopic site are urged to establish their own irrigation network, this 
is essential for the further maintenance and growth of the endometriotic lesion. It is widely 
known that VEGF is crucial for the process of angiogenesis; this is the process by which new 
blood vessels can be developed from preexisting ones. It has been shown that patients with 
endometriosis have a higher VEGF concentration in peritoneal fluid than endometriosis free 
women (Mahnke et al., 2000). Moreover, it was seen that VEGF stimulates COX-2 expression 
(Tamura et al., 2006) and that PGE2 increases VEGF production (Gately & Li, 2004; Liu et al., 
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2002); as it happens with aromatase, a positive feedback loop is established in which COX-2 
activity and PGE2 production are favored, giving the characteristic inflammation site of 
endometriosis (Figure 2). 
3.4 Prostaglandins as immune and inflammatory mediators in endometriosis 
Immune dysfunction has been proposed to play an important role in endometriosis 
(Dmowski W.P. & Braun, 2004; Vinatier et al., 1996). Peritoneal macrophages may play a key 
role in this respect, and may control the function of other immune cells. One of the altered 
mechanisms involved in the implantation and propagation of endometrial tissues 
ectopically is the decrease of the phagocytic ability of peritoneal macrophages (Chuang et 
al., 2009).  
In their earlier studies, Braun and coworkers reported that the decrease in peritoneal 
macrophages cytotoxic function is controlled by PG synthesis (Braun et al., 1992) (Figure 2). 
To elucidate the molecular mechanism implicated in the reduced phagocytic ability of 
peritoneal macrophages in endometriosis, recent in vitro and in vivo studies demonstrated 
that PGE2, via the EP2 receptor-dependent signaling pathway, inhibits the expression of the 
scavenger receptor CD36 in peritoneal macrophages. Reduced expression of any one of the 
scavenger receptors may result in loss of phagocytic ability of macrophages (Chuang et al., 
2010). Another work suggests that the expression and the enzymatic activity of MMP-9, a 
metalloproteinase that plays important roles in the scavenger activity of macrophages, is 
reduced by PGE2 in peritoneal macrophages derived from endometriosis patients compared 
to controls (Wu et al., 2005a). Wu and coworkers also reported that this inhibitory effect of 
PGE2 may be mediated via the EP2/EP4-dependent PKA pathway (Wu et al., 2005a). These 
data allow us to explain some of the disruptions observed in the endometriotic macrophage 
functions and provide a functional link between COX-2 overexpression and endometriosis 
development (Ota et al., 2001; Tamura et al., 2002; Wu et al., 2005b). 
There is abundant evidence demonstrating that endometriosis is accompanied by 
inflammatory reactions in the peritoneum, resulting in abnormal levels of a variety of 
cytokines, chemokines and pro-inflammatory factors in the peritoneal fluid (Gazvani & 
Templeton, 2002; Lousse et al., 2010). It is also well known, that the number of macrophages 
is increased in the peritoneal fluid of endometriosis patients and that they are in a  
hyperactive state (Halme & Surrey, 1990; Raiter-Tenenbaum et al., 1998). Production of 
inflammatory cytokines by these macrophages such as monocyte chemoattractant protein 
(MCP)-1, IL-1ǃ, TNF-ǂ and IL-6 is also increased in peritoneal fluid (Wu et al., 2007). As 
well, we found that the release of PGE2 by peritoneal macrophages was 100-fold higher in 
advanced endometriosis patients than in controls (Raiter-Tenenbaum et al., 1998). 
It has also been demonstrated that the overexpression of COX-2 is markedly induced by IL-
1ǃ, TNF-ǂ and MIF and that these pro-inflammatory agents strongly stimulate the 
production of PGE2 (Carli et al., 2009; Wu et al., 2002) (Figure 2). However, not only the 
overexpression of COX-2 increases the production of PGE2, but also a decrease in the 
deactivating enzyme 15-PGDH was found, showing an imbalance between eicosanoid 
biosynthesis and degradation in endometriosis patients compared with controls (Lousse et 
al., 2010). As a result, the concentration of PGE2 in the peritoneal fluid is elevated in patients 
with endometriosis, which leads to a more severe pathological process. 
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Macrophages synthesize and liberate PGE2, VEGF, MIF, IL-1ǃ, TNF-ǂ; all of these factors stimulate the 
expression and/or activity of COX-2 producing higher concentrations of PGE2. The high levels of PGE2 
stimulate the expression of the angiogenic factor VEGF and the steroidogenic capacity of endometriotic 
cells by the upregulation of StAR and aromatase, which augments the byosinthesis of estrogen. E2 and 
PGE2 further induce FGF-9 expresion to stimulate endometriotic cell proliferation. As a result, 
angiogenesis and cell proliferation are augmented while apoptosis is inhibited. Moreover, PGE2 
suppresses the phagocytic ability of macrophages, which fail to phagocytase the retrograde endometrial 
tissue and allow the implantation and proliferation of endometriotic lesion.  
A: androstenedione; AA: arachidonic acid; Arom: aromatase P450; COX-2: cyclooxygenase-2; E2: 
estradiol; IL-1┚: interleukin 1ǃ; MIF: macrophage migration inhibitory factor; PGE2: prostaglandin E2; 
StAR: steroidogenic acute regulatory protein; TNF-┙: tumor necrosis factor ǂ; VEGF: vascular 
endothelial growth factor; FGF-9: fibroblast growth factor-9. 
Fig. 2. Peritoneal environment in endometriosis 
4. Prostaglandins and pelvic pain 
Endometriosis has been traditionally included among the most important causes of pelvic 
pain in women of reproductive age. A recent case-control study described that 73% of 
women with endometriosis reported experiencing abdominopelvic pain, dysmenorrhea, or 
menorrhagia compared with only a 20% of the controls (Ballard et al., 2008).  
The role of PGs has been examined in women suffering from heavy menstrual bleeding and 
dysmenorrhea (Maybin et al., 2011). Dysmenorrhea is defined as the excessive pain during 
menstruation; and menorraghia or heavy menstrual bleeding is the excessive menstrual 
blood loss during the menstrual periods. These may be primary disorders or secondary to 
endometrial pathology such as endometriosis (Maybin et al., 2011; Tietjen et al., 2006).  
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The pelvic pain of dysmenorrhea has been demonstrated to be mediated through the action 
of PGE2 and a direct relationship between the severity of dysmenorrhea and the production 
of PGs has been observed in endometriosis (Coco, 1999; Koike et al., 1992; Nasir & Bope, 
2004). As well, analysis of menstrual fluid from women suffering from dysmenorrhea 
revealed augmented levels of PGE2 and PGF2ǂ (Dawood & Khan-Dawood, 2007a, 2007b; 
Lumsden et al., 1983). 
Increased synthesis of PGE2 and PGF2ǂ in the endometrium has important implications for 
menstruation (Baird et al., 1996). PGE2 is a potent vasodilator leading to increased oedema 
and contributing to pain at time of menstruation. Increased COX-2 and enhanced PGE2–EP-
induced cAMP production has been found by Smith and coworkers in the endometrium of 
women with objective heavy menstrual bleeding. These authors suggest that the increased 
expression of the rate-limiting COX enzymes in the endometrium of women with heavy 
menstrual blood loss will lead to an increase in PG production and to a magnified 
inflammation (Smith et al., 2007).  
In addition, there is well reported evidence for the hyperalgesic properties of PGs; and EP 
receptors have been shown elevated in sensory neurons that lead to increased pain 
perception (Bley et al., 1998; Levine & Taiwo, 1990). Wienecke and coworkers also 
demonstrated that PGE2 induces headache in healthy subjects by sensitization of cranial 
perivascular sensory afferents (Wienecke et al., 2009). Therefore, PG inhibition usually 
resolves the pain and many studies have demonstrated the efficacy of NSAIDs and specific 
COX-2 inhibitors in relieving dysmenorrheic pain (Coco, 1999; Hayes & Rock, 2002). 
Suprofen, ibuprofen and acetaminophen were shown to be efficient not only for pain relief 
but for menstrual fluid PGs suppression as well (Dawood & Khan-Dawood, 2007a, 2007b).  
A recent study suggests that the major modality to substantially alleviate pain in 
endometriosis is suppression of ovarian function and induction of a steady hormonal 
condition, anovulation and, eventually, amenorrhea (Vercellini et al., 2011). Hormonal 
manipulation and surgery have been found to be efficient in the management of pelvic pain 
associated to endometriosis (Vercellini et al., 2011). Oral contraceptives, GnRH agonists, 
danazol and progestins have been shown to reduce the production of PGs, which are 
responsible in large part for pelvic pain (Crosignani et al., 2006; Venturini et al., 1997).  
Given that, further investigations should focus on how to inhibit the production of PGs in 
endometriosis to control the pain and the development of the pathology. 
5. Endometriosis and its therapies 
As an estrogen-dependent disease, endometriosis treatment has aimed at reducing estrogen 
concentrations with reversible therapies, using oral contraceptives in a cyclical or 
continuous fashion as well as with GnRH analogues as first line medical treatments. 
Progestins, aromatase inhibitors (AIs) and, less frequently, androgens are also used. 
Removing lesions in a conservative surgery, or even having a radical intervention when the 
extent of the disease is major, is the surgical approach nowadays available. The most 
ordinary way of treating endometriosis is attacking from both flanks, with the surgical 
intervention and dealing with the symptoms with the drug therapy. In any case, the disease 
is likely to reappear after cessation of therapy; in fact, recurrence rate for endometriosis is 
between 4-25% (Meuleman et al., 2011).  
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5.1 PGE2 synthesis inhibition and pain treatment 
One of the most inhabilitating symptoms of endometriosis for carrying a normal life is the 
elevated pelvic pain patients experience. It includes pain before and during periods, during 
sexual intercourse, while urinating or defecating and during menstruation. It has been of great 
importance to provide the patient with a better quality of life ameliorating pain symptoms. 
Elevated concentrations of PGE2 in peritoneal fluid from endometriosis patients is the major 
cause thought to be involved in pain and inflammation processes (Wu et al., 2002). 
There have been done a large number of studies focusing on the inhibition of COXs activity. 
Whether it is blocking simultaneously COX-1 and COX-2 or with selective COX-2 inhibitors, 
the ultimate goal is to lower the concentrations of PGE2. 
NSAIDs, among them: ibuprofen, naproxen, diclofenac or aspirin; are used primarily for 
pain treatment, from a headache to menstrual cramps, from a backache to treating an 
inflammation due to a sprain. These NSAIDs are non-selective COX inhibitors; this means 
that they prevent the synthesis of PGs from both COXs. Of course, as a constitutively and 
ubiquitously expressed enzyme, COX-1 inhibition has side effects that should be avoided. 
Gastrointestinal ulcer is not a rare effect after long term inhibition of COX-1 (Wadman, 
2007); this is why COX-2 selective inhibitors have been developed.  
Celecoxib belongs to the family of NSAIDs with high selectivity for COX-2 inhibition. Other 
coxibs have been developed too (rofecoxib, valdecoxib) but were withdrawn from the 
market in the mid 2000s by the Federal Drug and Food Administration (FDA) of the United 
States of America because they were proven to have serious cardiovascular adverse events. 
Coxibs were and are mostly used in arthritis; the one still available for purchase, celecoxib, 
is prescribed in familial adenomatous polyposis and as an adjuvant in breast cancer (Basu et 
al., 2006; Falandry et al., 2009; Iwama, 2009; Jankowski & Hunt, 2008; Lynch et al., 2010). 
Celecoxib has not been approved yet for the treatment of endometriosis. There is one study 
that evaluated the effectiveness of a COX-2 specific inhibitor on relieving pain symptoms 
associated to endometriosis after a conservative surgery. Cobellis and coworkers 
demonstrated in their study that rofecoxib was effective for the management of pain and no 
recurrence occurred during the six months of treatment (Cobellis et al., 2004). 
Ferrero and coworkers, recently published a review where they compilated information on 
the use of AIs and how they contributed to diminish endometriosis related pain. This 
systematic study shows that the AIs, letrozole and anastrozole, are effective in treating pain 
symptoms; when withdrawn symptoms reappear, but they cannot be used for a long term 
therapy because of the adverse effects these compounds have on bone density (Ferrero et al., 
2011). Endometriosis patients need chronic treatment, and this could be achieved combining 
AIs with a hormonal therapy to reduce the loss of bone density (Ferrero et al., 2011). 
5.2 PGE2 synthesis inhibition and the control over endometriosis development 
There have been conducted several studies in which AIs were used and the progression of 
endometriosis was evaluated. When letrozole or anastrozole were added to endometrial 
epithelial cells from endometriosis patients in culture, cell proliferation was inhibited and 
apoptosis augmented (Meresman et al., 2005). When the same two compounds were used 
for the treatment of surgically induced endometriosis in mice, not only cell proliferation was 
diminished and apoptosis increased within the endometriotic like lesion, but PGE was also 
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decreased in the peritoneal fluid of mice treated with letrozole but not with anastrozole 
(Bilotas et al., 2010). 
Much research has been done evaluating the effects of inhibiting COXs activity regarding 
the development of endometriosis with in vivo and in vitro approaches. Celecoxib has been 
shown to have anti-proliferative and pro-apoptotic effects over endometrial epithelial cells 
in culture obtained from biopsies of women with and without endometriosis; it was also 
effective in diminishing COX-2 expression, reducing the synthesis of VEGF and PGE2 
(Olivares et al., 2008). Similar results had previously been achieved in various cancer models 
(Basu et al., 2005; Chun & Surh, 2004). Given that the endometrial cells at the ectopic site 
have a very similar behaviour to neoplasic cells; it is not surprising that treatments aim at 
the same targets. 
There is one very complete work from Efstathiou and coworkers where they compared 
seven different selective (rofecoxib and celecoxib) and non-selective (aspirin, ibuprofen, 
indomethacin, naproxen and sulindac) NSAIDs on the establishment and development of 
endometriosis in a mouse model (Efstathiou et al., 2005). In this work, celecoxib given orally 
twice daily and indomethacin administered subcutaneously daily for four weeks, were both 
effective in significantly diminishing the percentage of established lesions compared to the 
control group. All the NSAIDs evaluated in the same study, except for aspirin, significantly 
inhibited the growth of the established lesions compared to the control group (Efstathiou et 
al., 2005). A study in a rat model of endometriosis, evaluated the effect of parecoxib, another 
selective COX-2 inhibitor, and showed not only a significant reduction in lesion size, but 
also, a significant inhibition on the expression of VEGF, its receptor Flk-1 and COX-2 
compared to the untreated group with endometriosis (Machado et al., 2010). Machado and 
coworkers also observed a significant reduction of the levels of PGE2 in endometriotic 
homogeneized tissue treated with parecoxib compared to the untreated group (Machado et 
al., 2010). 
More recently a new approach targeting more than one molecule to prevent the 
development of the disease has gained importance. Promising results were achieved firstly 
in cancer models, which targeted COX-2 and PPARǄ. This combinational therapy resulted in 
the inhibition of cell proliferation and apoptosis enhancement in vitro and increased overall 
survival rate in vivo (Mustafa & Kruger, 2008; Sun et al., 2009). When celecoxib was 
combined with rosiglitazone, a PPARǄ agonist, for the treatment of surgically induced 
endometriosis in a mouse model, a reduced number of established lesions was observed as 
well as the volume of established ones; also induction of apoptosis and reduction of the cell 
proliferation rate and vascularization was achieved (Olivares et al., 2011). 
Reducing PGE2 concentration in the peritoneal environment would not only be relieving the 
pain caused by the disease but would also be affecting its development. This is one of the 
main goals of endometriosis treatments; now it is time to decide whether the drugs used to 
achieve these results are the appropriate ones to manage with this disease. 
6. Conclusion 
In conclusion, PGs play a substantial role in the physiological and pathological processes in 
the reproductive system. PGs are known to be involved in the initiation of the 
phsysiological implantation and decidualization. Also, COX-2 and PGE2 were seen to be 
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overexpressed in several pathological circumstances as different types of cancers and other 
inflammation related diseases.  
There is no doubt that PGE2 is implicated in the aetiopathogenesis of endometriosis and 
contributes to the development and maintenance of the disease. The elevated levels of PGs 
found in the peritoneal fluid from patients with endometriosis are mainly produced by 
peritoneal macrophages and endometriotic tissues. As well, the peritoneal estrogens, pro-
inflammatory and pro-angiogenic molecules contribute to elevate the expression of COX-2 
and consequently the levels of PGE2 in endometriosis patients. The pelvic pain associated to 
endometriosis has also been demonstrated to be mediated through the action of PGE2 and 
inhibition of PG production usually resolves the pain.  
Given these data, further investigations should focus on how to inhibit the production of 
PGs in endometriosis, to control the pain and the development of the pathology. 
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